Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures                 of impairment and disability

Hoogervorst, Erwin L.J.; Zwemmer, Jack; Jelles, B.; Polman, Chris H.; Uitdehaag, Bernard M. J.

doi:10.1191/1352458504ms1078oa

Cited by 82 publications

(64 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to being internally consistent and reproducible, this scale has been shown to correspond to several well established generic health impact scales [14] and clinician assessed disability. [15][16][17] …”

Section: Introductionmentioning

confidence: 98%

Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis

Hayton¹,

Furby²,

Smith³

et al. 2011

J Neurol

View full text Add to dashboard Cite

The association of pathology and neurological deficit with quality of life (QoL) in multiple sclerosis (MS) is not fully understood. In this study, magnetic resonance imaging (MRI) measures of pathology--T1 and T2 lesion volume and ratio; active T2 lesion number; global and regional brain volume and atrophy; magnetization transfer ratio (MTR) for lesions, normal appearing grey and white matter (NAGM, NAWM); and spinal cord cross-sectional area-and measures of neurological disability (expanded disability status scale, EDSS), deficit (MS functional composite, MSFC) and inflammatory activity (relapse rate) were compared with the MS impact scale (MSIS-29), in participants in a trial of lamotrigine in secondary progressive MS. Data were collected from 118 people (85 female:33 male) aged 30-61 years (mean 50.6 years)--median EDSS 6.0 (range 4.0-7.5); mean disease duration 20.1 years (range 3-41)--at baseline and 2 years. Regression analysis was used to identify independently significant cross-sectional and longitudinal correlates of the physical (MSIS-phys) and psychological (MSIS-psych) components of the MSIS-29; longitudinal analysis using the 57 people in the placebo arm. The only independently significant correlate of MSIS-phys was 1/timed walk (TW) (p < 0.0001, R (2) = 0.13; p = 0.047, R (2) = 0.09); cross-sectionally the best model for MSIS-psych was the paced auditory serial addition test (PASAT-3) (p = 0.041) and T1-to-T2 lesion volume ratio (p = 0.009) (R (2) = 0.13); longitudinally it was change in 1/TW (p = 0.007), mean NAWM MTR (p = 0.003) and NAGM peak height (p = 0.048) (R (2) = 0.32). These data show that MRI measures and clinical measures do impact on quality of life, but the association is limited.

show abstract

Section: Introductionmentioning

confidence: 98%

Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis

Hayton¹,

Furby²,

Smith³

et al. 2011

J Neurol

View full text Add to dashboard Cite

show abstract

“…It consists of 29 questions, among which 20 address the physical impact component, and nine assess the psychological impact. A score is thus generated and reported on a scale from 0 to 100, on which lower scores indicate better quality of life [16][17][18] . The Timed 25-foot Walk (T25FW) was carried out on an area painted with a white strip, measuring 7.62 meters (25 feet), in a corridor at CATEM with an anti-slip floor surface.…”

Section: Methodsmentioning

confidence: 99%

Cross-cultural adaptation and validation of the 12-item Multiple Sclerosis Walking Scale (MSWS-12) for the Brazilian population

Marangoni¹,

Pavan²,

Tilbery³

2012

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Gait impairment is reported by 85% of patients with multiple sclerosis (MS) as main complaint. In 2003, Hobart et al. developed a scale for walking known as The 12-item Multiple Sclerosis Walking Scale (MSWS-12), which combines the perspectives of patients with psychometric methods. OBJECTIVE: This study aimed to cross-culturally adapt and validate the MSWS-12 for the Brazilian population with MS. METHODS: This study included 116 individuals diagnosed with MS, in accordance with McDonald's criteria. The steps of the adaptation process included translation, back-translation, review by an expert committee and pretesting. A test and retest of MSWS-12/BR was made for validation, with comparison with another scale (MSIS-29/BR) and another test (T25FW). RESULTS: The Brazilian version of MSWS-12/BR was shown to be similar to the original. The results indicate that MSWS-12/BR is a reliable and reproducible scale. CONCLUSIONS: MSWS-12/BR has been adapted and validated, and it is a reliable tool for the Brazilian population.

show abstract

“…Although the American Committee considers the Multiple Sclerosis Functional Composite Measure (MSFC) to be a standard test because it evaluates the motor performance of the upper limbs (UL) and LL, along with cognition 15,16 , there are points that are not fully covered by this form of assessment, when gait is considered. A more complex test such as SSST may increase the sensitivity of this evaluation, but before it is fully used in Brazil, it needs to be validated.…”

Section: Reliability Testmentioning

confidence: 99%

“…Although the EDSS is the most widely used scale for MS evaluation 15 , and is considered to be the gold standard, its application is limited only to doctors, since there is an evaluation of several functional systems. The authors agree with Nieuwenhuis et al, 2006 5 who said that this is not a linear scale, and its psychometric properties are not reliable, since it is not entirely objective and incorporates some subjective variables.…”

Section: Reliability Testmentioning

confidence: 99%

Validation of the "Six Step Spot Test" for gait among patients with multiple sclerosis in Brazil

Pavan¹,

Tilbery²,

Lianza³

et al. 2010

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

The clinical manifestations of multiple sclerosis (MS) are variable among patients, and the course of disease is not linear. Different symptoms are presented, with gradual accumulation of disability. These variations are difficult to quantify in clinical practice, and several studies have attempted to create instruments capable of measuring these disabilities. The Six Step Spot Test (SSST) was developed for quantitative evaluation of the lower limbs (LL) over time. Performance in this test reflects the complexity of sensory-motor function, including LL strength, spasticity, coordination and balance, going beyond vision and cognition. The aim of the present study was to validate the SSST in a population of MS patients in Brazil. This prospective study included 75 patients with MS, with EDSS 0 to 6.5 in the study group. Ninety-one healthy subjects were randomly selected for the control group. The results showed that the groups were similar, and that the SSST is a reliable and reproducible test. According to the statistical analysis on the data in this study, the SSST is a valid, reliable and reproducible tool for use in the Brazilian MS patient population. Key words: gait, multiple sclerosis, disability evaluation, validation studies, reproducibility of results.Validação do teste de marcha "six step spot test" em pacientes com esclerose múltipla no brasil resumo As manifestações clínicas da esclerose múltipla (EM) são variáveis e o curso da doença não é linear, caracterizado por sintomas, acúmulo progressivo de incapacidades. Estas variações são difíceis de quantificar na prática clínica, motivo pelo qual surgiram diversos estudos para criação de instrumentos capazes de mensurar essas incapacidades. O Six Step Spot Test (SSST) foi desenvolvido para avaliar função dos membros inferiores (MMII) de forma quantitativa, mensurado no domínio tempo, avaliando a complexa função sensório-motora, como força em MMII, espasticidade, coordenação e equilíbrio, além da visão e cognição. Este estudo teve como objetivo validar o SSST para pacientes com EM no Brasil. Estudo prospectivo do qual participaram 75 pacientes com EM e EDSS de 0 a 6,5 no grupo de estudo e 91 indivíduos saudáveis no controle que foram selecionados aleatoriamente. Segundo os dados estatísticos deste estudo, o SSST é válido, confiável e reprodutível para pacientes com EM no Brasil. Palavras-chave: marcha, esclerose múltipla, avaliação da deficiência, estudos de validação, reprodutibilidade dos testes.

show abstract

Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability

Cited by 82 publications

References 19 publications

Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis

Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis

Cross-cultural adaptation and validation of the 12-item Multiple Sclerosis Walking Scale (MSWS-12) for the Brazilian population

Validation of the "Six Step Spot Test" for gait among patients with multiple sclerosis in Brazil

Contact Info

Product

Resources

About